SecBot SecBot
8-K ·Filed Nov 5, 2026

CRVS

Corvus Pharmaceuticals, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed11d 10h ago SEC0001171843-26-007175
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor upcoming data catalysts: Angel Pharma cohort 1 atopic dermatitis topline in March 2027, HS Phase 1b initial data in 1H 2027, and ALPS ASH poster presentation in December 2026. Cash runway into Q2 2028 provides no near-term financing pressure.

DirectionNeutral
Confidencehigh
Horizonmonths

soquelitinib

● Neutral Named in this 8-K
Impact
Phase
Phase 3 (registrational for PTCL); Phase 2 (atopic dermatitis, ALPS); Phase 1b (hidradenitis suppurativa)
Time to market
If the Phase 3 PTCL trial succeeds at its interim futility analysis (Q1 2027) and final readout (estimated primary completion November 2027), a potential NDA submission could occur in 2028, with FDA approval possible in 2029 at the earliest. The atopic dermatitis program is earlier-stage (Phase 2 topline in Q3 2027) and would require additional Phase 3 trials before any regulatory submission.
Next catalyst
None dated

What to watchThe next major binary catalyst is the Phase 3 PTCL interim futility analysis expected in Q1 2027 (roughly 2-5 months away). A positive result would validate soquelitinib's novel ITK-inhibitor mechanism in oncology and support continued enrollment toward the primary completion in late 2027. A futility stop would severely damage the thesis. Separately, the SIERRA1 atopic dermatitis Phase 2 topline data in Q3 2027 will test the drug's potential in a large immunology market. The ASH 2026 poster (Dec 14) on ALPS data (n=3) is an early readout with limited stock-moving potential.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$10.54
T+0 close · Nov 5, 2026 · via day close
Latest settled
+0.95%
T+5 · $10.64 · next T+20 in 20d
Vs SPY
−1.65%
α at T+5
Latest observation
+1.93%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $10.54entry
  2. T+1 · 8d ago +7.68%α +5.32% · $11.35
  3. T+5 · 4d ago +0.95%α −1.65% · $10.64
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Corvus Pharmaceuticals reported Q3 2026 net loss of $20.3M, wider than the $10.2M loss in Q3 2025, driven by higher R&D costs for soquelitinib trials. Cash runway extends into Q2 2028 with $202.9M at quarter end. Key pipeline milestones include ALPS Phase 2 positive initial data, Angel Pharma cohort 1 enrollment complete with topline data expected March 2027, and Phase 1b HS trial enrolling with initial data in 1H 2027.

Key Financial Metrics

EPS
−$0.22

Key Facts

  • Net loss for Q3 2026 was $20.3M vs $10.2M in Q3 2025
  • Cash, cash equivalents and marketable securities of $202.9M at September 30, 2026
  • Cash runway expected into Q2 2028
  • R&D expenses $17.8M in Q3 2026 vs $8.5M in Q3 2025
  • ALPS Phase 2 trial initial data published; all 3 patients had positive response
  • Angel Pharma completed enrollment in cohort 1 of Phase 1b/2 atopic dermatitis trial; topline data March 2027
  • Phase 1b hidradenitis suppurativa trial enrolling; initial data 1H 2027
  • Phase 2 asthma trial to initiate by Q1 2027

Financial Impact

Net loss widened to $20.3M from $10.2M YoY; cash burn $17.8M R&D spend in quarter

net losscashR&D expenses

Risk Factors

  • Net loss widening significantly YoY with no approved products or revenue
  • Clinical-stage biotech with binary data readouts ahead
  • Higher R&D spend may accelerate cash burn if trials expand

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-007175
Document: f8k_110526.htm0001171843-26-007175
Document: 0001171843-26-007175-index-headers.html0001171843-26-007175
Document: 0001171843-26-007175-index.html0001171843-26-007175
Document: 0001171843-26-007175.txt0001171843-26-007175
8-K Data (Synthetic)0001171843-26-007175

Track record

15 reports on CRVS

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +2.61% at T+1 after the Mar 12, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 13, 20263d ago Insider Buy Neutral 3/10 Entry $11.20 Now $10.60 −5.36% settles Feb 12
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $11.37 Now $10.60 −6.77% settles Feb 8
  3. Nov 5, 202611d ago 8-K Neutral 4/10 Viewing Entry $10.54 Now $10.60 +0.57% settles Feb 4
  4. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
  5. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $10.57 Now $10.60 +0.28% settles Feb 2
  6. Sep 30, 20266w ago Press Release Neutral 3/10 Entry $10.93 Now $10.60 −3.02% settles Dec 28
  7. Aug 21, 202612w ago Institutional Cluster Bullish 6/10 Entry $14.46 to $10.60 Now $10.60 −26.69% ▼ −26.69% −23.33% vs SPY
  8. Jul 22, 202616w ago 8-K Neutral 2/10 Entry $13.68 to $9.85 Now $10.60 −22.51% ▼ −28.00% −32.55% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $11.60 to $14.39 Now $10.60 −8.62% ▲ +24.05% +19.66% vs SPY
  10. May 14, 202626w ago 8-K Bullish 7/10 Entry $13.66 to $13.74 Now $10.60 −22.37% ▲ +0.62% −2.97% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026